
|Videos|January 18, 2023
The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer
Author(s)Stephen J. Freedland, MD
Dr Stephen J. Freedland muses on how the utilization of AR pathway inhibitors and docetaxel in earlier lines of prostate cancer treatment has impacted subsequent treatment selection in mCRPC.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC
2
Kathryn Gessner, MD, PhD, on the challenges of selecting patients for bladder preservation
3
First-in-human bladder transplant demonstrates sustained function at 6 months
4
Experts discuss the challenge of detecting CIS in bladder cancer
5













